The important part:
The current shortage of stimulant medications is the result of many factors. It began last fall due to a manufacturing delay experienced by one drug maker. While this delay has since resolved, we are continuing to experience its effects in combination with record-high prescription rates of stimulant medications. Data show that, from 2012 to 2021, overall dispensing of stimulants (including amphetamine products and other stimulants) increased by 45.5 percent in the United States. According to a U.S. Centers for Disease Control and Prevention report, particularly during 2020-2021, when virtual prescribing was permitted on a widespread basis during the COVID-19 Public Health Emergency, the percentages in certain age groups grew by more than 10 percent. We are calling on key stakeholders, including manufacturers, distributors, pharmacies, and payors, to do all they can to ensure access for patients when a medication is appropriately prescribed. We want to make sure those who need stimulant medications have access. However, it is also an appropriate time to take a closer look at how we can best ensure these drugs are being prescribed thoughtfully and responsibly.
Stimulants are controlled substances with a high potential for abuse, which can lead to addiction and overdose. Therefore, there are limits (also known as quotas) set by DEA for how much of these drugs can be produced. However, for amphetamine medications, in 2022, manufacturers did not produce the full amount that these limits permitted them to make. Based on DEA’s internal analysis of inventory, manufacturing, and sales data submitted by manufacturers of amphetamine products, manufacturers only sold approximately 70 percent of their allotted quota for the year, and there were approximately 1 billion more doses that they could have produced but did not make or ship. Data for 2023 so far show a similar trend.
We (DEA and the FDA) have called on manufacturers to confirm they are working to increase production to meet their allotted quota amount. If any individual manufacturer does not wish to increase production, we have asked that manufacturer to relinquish their remaining 2023 quota allotment. This would allow DEA to redistribute that allotment to manufacturers that will increase production. DEA is also committed to reviewing and improving our quota process.
I am curious if the limitations are due to lobbying from the manufacturers to create an artificial limit to the supply.
I wouldn’t be surprised based on how these manufacturers have operated in the past.
“Please daddy DEA don’t let me make more profits!”
No, this is just DEA being DEA. The DEA needs to be abolished.
If you artificially limit the supply of whatever drug, the demand for that drug is also artificially inflated. Companies being companies can then increase the price of the drug based on those figures and make more profit without having to spend time and resources making more of those drugs.
Limiting the manufacture of those drugs also ensures that the market doesn’t get flooded with too much of that drug, keeping a baseline floor price of that drug.
If the pharmaceutical companies were advocating for the patients I would believe that the DEA is being ridiculous, but that’s not what’s happening here. You have pharmaceutical companies not producing those medications to the limits already set.
With the logic of “please daddy afea Don’t let me make more profits!” You would think those pharmaceutical manufacturers would be making more, but they aren’t. So it isn’t the DEA being the DEA in this instance.
Thanks for explaining supply and demand for me. Have you heard of the insurance industry?
It’s the insurance industry which pays the bill. So your argument is that the pharma companies are just not interested in making money, since we all know that the insurance industry sets the prices they are willing to pay.
Patients have no skin in the game. They just pay their premiums and take their meds. Their costs do not increase. Uninsured people aren’t paying hundreds of dollars a month for meds.